Literature DB >> 9101366

Secretory products of breast cancer cells specifically affect human osteoblastic cells: partial characterization of active factors.

B Siwek1, M Lacroix, C De Pollak, P Marie, J J Body.   

Abstract

The pathogenesis of tumor-induced osteolysis (TIO) following breast cancer metastases in bone remains unclear. We postulated that osteoblasts could be target cells for the secretory products of breast cancer cells. We previously showed that serum-free conditioned medium (CM) of the breast cancer cell line MCF-7 inhibits DNA synthesis by 75% of control values in osteoblast-like cells SaOS-2 and that this effect is only in a minor part due to transforming growth factor beta secretion. To establish the specificity of our observations and to look for other biologically active factors, we have tested the effects of medium conditioned by several cancer and noncancer cell lines (breast, colon, placenta, or fibrosarcoma) on the proliferation of osteoblast-like cells (SaOS-2, MG-63), normal human osteoblasts, human fibrosarcoma cells, and normal human fibroblasts. Culture medium (1:2) of the breast cancer cell lines MCF-7, T-47D, MDA-MB-231, and SK-BR-3 inhibited by 25-50% the proliferation of osteoblast-like cells SaOS-2, MG-63, and normal osteoblasts as evaluated by the MTT survival test or [3H]thymidine incorporation. MCF-7 cells completely inhibited the proliferation of normal human osteoblasts in coculture. This inhibitory effect was reversible and not due to cytotoxicity. Moreover, the cyclic adenosine monophosphate (cAMP) response to parathyroid hormone (PTH) of osteoblast-like cells SaOS-2 was also increased by 100-240% by the same CM. Such activities were, however, not detected in medium from the breast noncancer cell line HBL-100 or in the medium conditioned by non-breast cancer cell lines (COLO 320DM, HT-29, JAR, or HT-1080). Medium from the breast cancer cells had no effect on normal human fibroblasts or fibrosarcoma cells (HT-1080), suggesting the specificity of their action on human osteoblasts. After partial purification by ultrafiltration and size-exclusion chromatography, we found that medium of T-47D cells contained at least three nonprostanoid factors of low molecular weights (apparent MW of 700, 1500, and 4000 D) which affected human osteoblast-like cells. These factors were heat stable and could be peptides without disulfide bonds. In summary, our data show that human breast cancer cells release soluble factors that inhibit osteoblast proliferation and increase their cAMP response to PTH, indicating that osteoblasts could be important target cells for breast cancer cells and could be involved in the process of TIO.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101366     DOI: 10.1359/jbmr.1997.12.4.552

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Metastatic breast cancer cells suppress osteoblast adhesion and differentiation.

Authors:  Robyn R Mercer; Chiaki Miyasaka; Andrea M Mastro
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 2.  The role of bisphosphonates as adjuvant therapy for breast cancer.

Authors:  J R Gralow
Journal:  Curr Oncol Rep       Date:  2001-11       Impact factor: 5.075

Review 3.  The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.

Authors:  E V McCloskey; J F Guest; J A Kanis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Bisphosphonates in the treatment of metastatic breast cancer.

Authors:  J J Body
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

5.  Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response.

Authors:  Mehdi Najar; Hussein Fayyad-Kazan; Wissam H Faour; Bassam Badran; Fabrice Journe; Laurence Lagneaux
Journal:  Inflamm Res       Date:  2016-10-25       Impact factor: 4.575

6.  Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors.

Authors:  M Koutsilieris; C Reyes-Moreno; I Choki; A Sourla; C Doillon; N Pavlidis
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

7.  Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.

Authors:  O Fromigue; N Kheddoumi; J-J Body
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.